Rani Therapeutics appoints Nicholas Maestas as CFO, approves 2026 Equity Inducement Plan

Rani Therapeutics Holdings, Inc.

Nicholas Maestas appointed CFO effective June 29, 2026, succeeding Svai Sanford.
Maestas previously CFO of Tempest Therapeutics; base salary $500,000, target bonus 75%.
Maestas receives inducement option for 2,000,000 shares vesting over 4 years.
Board approved 2026 Equity Inducement Plan reserving 5,500,000 shares for new hires.
Plan allows inducement grants under Nasdaq Rule 5635(c)(4) without stockholder approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.